To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Step Ahead Sanofi website

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

chronic-graft-versus-host-disease-cgvhd

chronic GRAFT-VERSUS-HOST DISEASE (cGVHD)

<h4>Efficacy and safety of belumosudil as compared with best available therapy for the treatment of chronic graft-versus-host disease in the US population Waller EK (USA)</h4>

<h4>Clinically meaningful improvement of modified Lee symptom scale in patients treated with belumosudil for steroid-refractory chronic GvHD: Evidence from real-world outcomes Kim D (Canada)</h4>

<h4>Efficacy and safety of belumosudil for treatment of cGvHD: multicenter retrospective analysis of the French cohort of the compassionate use program Loschi M (France)</h4>

<h4>Exploring the impact of chronic graft-versus-host disease on the health-related quality of life of patients and caregivers: a qualitative survey-based study in France Kiprijanovski D (France)</h4>

<h4>Impact of belumosudil treatment in advanced chronic graft-versus-host disease (cGvHD): insights into response-based T- and B-cell subpopulation dynamics Ponce D (USA)</h4>

<h4>Description of patients and management of cGvHD in France based on natural language processing (NLP) from medical documents available in hospital electronic medical files Kiprijanovski D (France)</h4>

<h4>Living with GvHD - impact and experience Barata A (USA)</h4>

<h4>Incidence of graft versus host disease according to prophylaxis strategy in matched related and unrelated donor allogeneic hematopoietic stem cell transplantation: realworld experience of GETH-TC Bento L (Spain)</h4>

<h4>Challenges and opportunities of biomarkers in GvHD Greinix HT (Austria)</h4>

<h4>Grade your GvHD yourself - development of an app to document chronic graft-versus-host disease by patients and caregivers Denk A (Germany)</h4>

Abbreviations: 
 ADS, automated data structuration; AE, adverse event; aGvHD, acute graft-versus-host disease; AI-NLP, artificial intelligence natural language processing; allo-HSCT, allogenic hematopoietic stem-cell transplantation; ATG, ati-thymocyte globulin; BAFF, Bcell activating factor; BAT, best available therapy; BID, twice daily; BEL, belumosudil; CD, cluster of differentiation; cGvHD, chronic graft-versus-host disease; CI, confidence interval; CNI, calcineurin inhibitor; CR, complete response; CTLA4; cytotoxic Tlymphocyte associated protein 4; CXCL10, C-X-C motif chemokine ligand 10; DKK3, dickkopf WNT signaling pathway inhibitor 3; ECP, extracorporeal photopheresis; FFS, failure-free survival; GETH-TC, Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy; GI, gastrointestinal; GvHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; HLA, human leukocyte antigen; HrQoL, helath realted quality of life; IL-15, interleukin-15; LOT, lines of therapy; LSS, Lee Symptom Scale; MCS, mental component score; mLSS, modified Lee symptom scale; MMP3, matrix metalloproteinase 3; MS17, mass spectrometry 17; MSD, matched sibling donor; MTX, methotrexate; MUD, matched unrelated donor; NIH, National Institutes of Health; NRM, non-relapse mortality; OPN, osteopontin; ORR, overall response rate; OS, overall survival; PCS, physical component score; PFS, progression-free survival; PR, partial response; PRO, patient-reported outcomes; PTCy, post-transplant cyclophosphamide; PTSD, post-truamatic stress disorder; QOL, quality of life; RCT, randomized controlled trial; REG3α, regenerating islet-derived 3-alpha; RUX, ruxolitinib; RWE, Real-world evidence; sR-cGvHD, steroid-refractory chronic graftversus- host disease; ST2, suppression of tumorigenicity 2; TEM, effector memory T cells; TIM 3, immunoglobulin and mucin domain 3.
 
 &nbsp;

References:

The Congress Connection: cGvHD and Transplant Key Takeaways in 2025

CHRONIC-GRAFT-VERSUS-HOST-DISEASE-CGVHD

TRANSPLANT

Between The Lines: GVHD, Episode 1 – Understanding the Foundation of Graft vs Host Disease

In this first episode of&nbsp;Between The Lines: GVHD, Dr. Francesca Kinsella, Consultant Haematologist at University Hospitals Birmingham and a leading expert in stem cell transplantation, cellular therapy, and GvHD management, is joined by Dr. Inas Al Najar, Consultant, Hematology &amp; Bone Marrow Transplant and Director of Undergraduate &amp; Advanced Programs.
Together, they provide a comprehensive introduction to Graft versus Host Disease (GvHD), discussing its immunological basis, clinical manifestations, and the importance of timely recognition and multidisciplinary care.

Key Insights from the Episode:
<ul>
 <li>GvHD is a complex immune-mediated complication of allogeneic stem cell transplantation.</li>
 <li>The episode outlines key differences between acute and chronic forms, including timing, symptoms, and underlying mechanisms.</li>
 <li>Emphasis is placed on early detection, collaborative care, and emerging strategies for prevention and management.</li>
</ul>

<h4>Development and psychometric validation of a new pediatric chronic GvHD (cGVHD) symptom scale for children and caregiver-proxies Williams K (USA)</h4>

<ul>
 <li>Project 2 is planned to evaluate psychometric testing of scale validity, reliability, and responsiveness (N=120; child-caregiver dyads). Also, determine the lowest age for Lee-scale comprehension by adolescents.</li>
 <li>Current status - recruiting patients.</li>
</ul>

<h4>Chronic GvHD: Nailing the diagnosis &amp; exam Epling P (USA)</h4>

<ul>
 <li>NIH scoring data3: The NIH scoring system for cGvHD includes performance scales (e.g., Karnofsky score), skin involvement (e.g., maculopapular rash, sclerotic features), and organspecific symptoms (e.g., dry eyes, GI symptoms). For example, a performance scale of 80 gives 1 point, skin involvement of 50% BSA gives 2 points, and mild dry eyes not requiring frequent eye drops gives no points.</li>
 <li>Key diagnostic Imaging and physical examination: Diagnostic imaging for GI cGvHD can reveal multifocal small bowel strictures, fluid and gas collections indicating complications like cecal perforation, and mucosal changes in the colon.4 Musculoskeletal symptoms include joint tightness and muscle weakness, often requiring a combination of physical therapy and medical interventions.5</li>
</ul>

<h4>Single center experience of belumosudil in children &lt;12 years, adolescents and young adults Ibrahimova A (USA)</h4>

<ul>
 <li>The ORR was 44%, with PR in 7 patients NR in 9. Among the 2 children &lt;12 years, 1 had a PR and 1 had NR. Organ-specific PRs were observed in skin, mouth, eyes, lungs, genitourinary, joints/fascia, GI tract, and liver. Corticosteroids were successfully weaned in 9 patients. Seven patients discontinued belumosudil due to lack of response, and 1 due to concurrent AEs.</li>
 <li>AEs: Bacterial infections, hepatotoxicity, thrombocytopenia, and QTc prolongation.</li>
</ul>

<h4>Real world outcomes of belumosudil for treatment of chronic graft-versus-host disease: A single center experience Modi B (USA)</h4>

<ul>
 <li>ORR: The best ORR observed was 46.7% (complete response: 6.7% + partial response: 40%) with a median time to best response of 108.5 days. ORR was 31.1% at 6 months and 33.4% at 12 months. Steroid dose reduction and infection rates: About 29% of the patients reduced their corticosteroid dose, and 20% of patients discontinued steroids. Patients on combination therapy with ruxolitinib and belumosudil had higher infection rates (61%) compared to those on belumosudil monotherapy (23%; p=0.01).</li>
 <li>Steroid dose reduction and infection rates: About 29% of the patients reduced their corticosteroid dose, and 20% of patients discontinued steroids. Patients on combination therapy with ruxolitinib and belumosudil had higher infection rates (61%) compared to those on belumosudil monotherapy (23%; p=0.01).</li>
</ul>

<h4>Real-world patient characteristics and treatment patterns in patients with chronic graftversus- host disease receiving belumosudil in the United States Yu J (USA)</h4>

<ul>
 <li>The mean (SD) age was 48.2 (17.4) years, with 56.9% male. Patients started belumosudil a median of 489 days post-cGvHD diagnosis, mainly in LOT 3 or later (81.8%). Prior treatments included ruxolitinib monotherapy (22.5%) and CNI. Belumosudil was used as monotherapy/corticosteroids (45.9%) or combination therapy (54.1%). The median duration of belumosudil LOT was 133 days (IQR; 60–276). By follow-up, 39.8% had discontinued, 27.1% switched, and 20.4% added therapies.</li>
 <li>Belumosudil was largely used after ≥3 prior LOTs, likely due to approval timing. Further research is needed to evaluate treatment sequencing and long-term outcomes.</li>
</ul>

<h4>Patient experiences with chronic graft-versus-host disease and its treatment in the United States: a retrospective social media listening study Cowden MA (USA)</h4>

<ul>
 <li>Treatment regimens for cGvHD are complex and expensive. 10.3% (n=132) of posts mentioned difficulties in accessing new treatments, while 8.3% (n=106) noted the financial burdens associated with care. These challenges underscore the need for better treatment options and support systems.</li>
</ul>

<h4>Harnessing machine learning to predict chronic GvHD: A novel risk stratification score Ramgopal A (Panama)</h4>

<ul>
 <li>With an overall accuracy of 59%, the model shows moderate predictive capability. Enhancing specificity and expanding data could improve accuracy, supporting early risk stratification and optimized HSCT treatment.</li>
</ul>

<h4>Acute and chronic graft versus host disease (GvHD) management in the Eastern Mediterranean region: Result of the Worldwide Network for Blood &amp; Marrow Transplantation (WBMT) global GvHD survey Muhsen IN (USA)</h4>

<ul>
 <li>cGvHD: Systemic steroids were the first-line treatment. For steroid-refractory cases, ruxolitinib (80%) was most used, followed by CNI (67%) and mycophenolate mofetil (53%). Only 20% had multidisciplinary teams, 10% enrolled steroid-refractory patients in trials, and 43% lacked an SOP.</li>
</ul>

<h4>Association of patient-reported outcomes with survival and graft versus host disease in allogeneic hematopoietic cell transplant recipients Ardila V (USA)</h4>

<ul>
 <li>Higher pre-HCT depression and distress were significantly associated with increased aGvHD and trends towards higher incidence cGvHD, NRM, and lower OS.</li>
</ul>

<h4>Impact of graft-versus host disease following allogeneic hematopoietic cell transplantation on leukemia free survival in hematologic malignancies: A CIBMTR Analysis Qayed M (USA)</h4>

<ul>
 <li>The cumulative incidence of relapse for AML was around 20%, with no significant differences in relapse rates based on GvHD grade. In AML patients with low/intermediate or high/very high DRI, no significant differences in cumulative incidence of relapse were found by GvHD severity. In patients with high or very high DRI also, no difference in cumulative incidence of relapse by severity of GvHD was found. However, severe aGvHD was associated with inferior LFS and higher HR for LFS.</li>
</ul>

Abbreviations AE, adverse event; aGvHD, acute graft-versus-host-disease; ALL, acute lymphoblastic leukemia; allo-HCT, allogenic hematopoietic cell transplantation; AML, acute myeloid leukemia; BSA, bovin serum albumin; CIBMTR, Center for International Blood and Marrow Transplant Research; cGvHD, chronic graft-versus-host-disease; CNI, calcineurin inhibitors; DRI, disease relapse index; EM, Eastern Mediterranean; FDA; Food and Drug Administration; GI, gastrointestinal; GvHD; graft-versus-host disease; HCP, healthcare professional; HCT, hematopoietic cell transplant; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation; IQR, interquartile range; LFS, leukemia-free survival; MH, mental health; ML, machine learning; NCCN DT, National Comprehensive Cancer Network Distress Thermometer; NIH, National Institute of Health; NR, no response; NRM, nonrelapse mortality; ORR, overall response rate; OS, overall survival; PCSS, pediatric cGvHD symptom scale; PH, physical health; PHQ-9, Patient Health Questionarie-9; PR, partial response; PRO, patient-reported outcome; PROMIS, Patient-Reported Outcomes Measurement Information System; PTSD, post traumatic stress disorder; QoL, quality of life; Qtc, corrected QT interval; SML, social media listening; SOP, standard operating procedure.

chronic GRAFT-VERSUS-HOST DISEASE (cGVHD)

Latest Articles

The Congress Connection: cGvHD and Transplant Key Takeaways in 2025

Between The Lines: GVHD, Episode 1 – Understanding the Foundation of Graft vs Host Disease

Tandem Meetings Transplantation and Cellular Therapy Meetings of ASTCT® and CIBMTR®